Page 112 - 84_02
P. 112
Food and drug adverse interactions: types, identification and update
5. Bermejo Vicedo T, Hidalgo Correas FJ, Pérez en lo que respecta al etiquetado de determinados
Menéndez Conde C. Interacciones entre fármacos y
productos alimenticios que contienen ácido
nutrientes. En Tratado de Nutrición. Tomo IV. glicirrícico y su sal amónica. Diario Oficial de la
Nutrición Clínica. Gil A (Ed.). Editorial Médica Unión Europea, n° L 162, de 30/04/2004: 0076–0077.
Panamericana: Buenos Aires. 2010, pp. 343-66. Disponible en: (http://eur-
6. Committee for Medicinal Products for Human Use lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELE
(CHMP). Guideline on the use of pharmacogenetic
X:32004L0077:ES:HTML)
methodologies in the pharmacokinetic evaluation of
20. FDA. Clinical Pharmacology Section of Labeling for
medicinal products. Ref. EMA/CHMP/37646/2009. Human Prescription Drug and Biological Products —
EMA, London, 12 Decembre 2011. Disponible en: Content and Format. Guidance for Industry. December
(http://www.ema.europa.eu/docs/en_GB/document_li 2016. Disponible en:
brary/Scientific_guideline/2012/02/WC500121954.pd (https://www.fda.gov/downloads/Drugs/GuidanceCo
f ). mplianceRegulatoryInformation/Guidances/UCM1097
7. EMEA Public Statement on the risk of drug interactions 39.pdf)
with Hypericum perforatum (St John’s wort) and 21. Hall SD, Wang Z, Huang SM, Hamman MA,
antiretroviral medicinal Products. Ref Vasavada N, Adigun AQ, y col. The interaction
between St John's wort and an oral contraceptive. Clin
EMEA/6321/00. London, 28 February 2000.
Disponible en: Pharmacol Ther 2003; 74: 525-35.
http://www.ema.europa.eu/docs/en_GB/document_lib 22. Jensen K, Ni Y, Panagiotou G, Kouskoumvekaki I.
rary/Public_statement/2010/08/WC500095655.pdf). Developing a molecular roadmap of drug-food
8. Guy C, Ollagnier M. Sucralfate and bezoars: data from interactions. PLoS Comput Biol 2015; 10(2):
the system of pharmacologic vigilance and review of
e1004048.
the literature. Therapie 1999; 54(1): 55-8.
23. Medicamentos sujetos a seguimiento adicional.
9. Madurga M. Farmacovigilancia: Los suplementos de ajo Agencia Española de Medicamentos y Productos
anulan los efectos de saquinavir (Fortovase®,
Invirase®). Panorama Actual Med 2002; 26 (251): Sanitarios (AEMPS). Disponible en:
(https://www.aemps.gob.es/vigilancia/medicamentosU
210-1. soHumano/seguimiento_adicional.htm)
10. Spence DJ. Drug interactions with grapefruit: Whose
responsibility is it to warn the public? Clin Pharmacol
Ther 1997; 61: 395-400.
11. Ötles S, Senturk A. Food and drug interactions: a
general review. Acta Sci Pol Technol Aliment 2014;
13(1): 89-102.
12. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T,
Hasegawa R. Undesirable effects of citrus juice on the
pharmacokinetics of drugs. Focus on recent studies.
Drug Safety 2005; 28(8): 677-94.
13. Bailey DG, Dresser G, Arnold JMO. Grapefruit-
medication interactions: Forbidden fruit or avoidable
consequences? CMAJ 2013; 185(4): 309-16.
14. Tatro DS. Update: Drug interactions with grapefruit
juice. Drug Link 2004; 8(5): 35-8.
15. University of Indiana. School of Medicine, Department
of Medicine, Clinical Pharmacology. Cytochrome
P450 Drug Interaction Table. Disponible en: (http://
http://medicine.iupui.edu/clinpharm/ddis/main-table)
16. Scott GN, Elmer GW. Update on natural product-drug
interactions. Am J Health-System Pharmacy 2002;
59(4): 339-47.
17. Lefebvre RE, Marc-Aurele L. Licorice and
hypertension. Can Med Ass J 1968; 99: 230-1.
18. Madurga M, Rodríguez Silva MJ, Abajo FJ de.
Regaliz: ¿fármaco o alimento? Atención Primaria
1995; 16(4): 233-4.
19. Directiva 2004/77/CE de la Comisión, de 29 de abril
de 2004, por la que se modifica la Directiva 94/54/CE
@Real Academia Nacional de Farmacia. Spain 225
